Category: clinical study retractions

Caught Our Notice: How can a publication be a surprise to a corresponding author?

Via Wikimedia

Title: Umbelliferone reverses depression-like behavior in chronic unpredictable mild stress-induced mice via RIP140/NF-κB pathway

What Caught Our Attention: One would think that the corresponding author would have to be aware that they are submitting an article for publication — but apparently not, as this retraction demonstrates. The 2016 paper listed two corresponding authors — along with both of their emails and mailing addresses — but according to the retraction notice, one of them did not give consent “in any form” to the publication. Often, we see authors unaware of the use of their name when their email has been faked, but here, it’s possible the journal simply relied on the other corresponding author for all correspondence. Continue reading Caught Our Notice: How can a publication be a surprise to a corresponding author?

US court denies virus researcher’s latest appeal challenging 7-year funding ban

Scott Brodie has almost run out of options.

A former professor at the University of Washington, Brodie is currently involved in his third lawsuit challenging a finding of scientific misconduct and a seven-year funding ban handed down in 2010 by the U.S. Department of Health and Human Services’ Office of Research Integrity. He says that in the time since his case was heard by an administrative law judge at the ORI level, new evidence has come to light that shows he “did not have a ‘full and fair opportunity to litigate’ the issues.” His lawsuit sought a court order to have the ORI revisit its decision.

Last year, a U.S. District Court judge dismissed the case, saying it revisited old issues that had already been litigated, but Brodie appealed that decision. Now, his quest may have come to an end: On Nov. 27, the U.S. Court of Appeals for the D.C. Circuit dismissed the appeal. If he wants to continue the case, Brodie’s only remaining option is to appeal the decision to the U.S. Supreme Court.

In the court order, the panel of three judges wrote:

Continue reading US court denies virus researcher’s latest appeal challenging 7-year funding ban

Caught Our Notice: What if you find out a paper relied on expired herbal supplement?

Via Wikimedia

Title: Exploration of inhibitory mechanisms of curcumin in lung cancer metastasis using a miRNA- transcription factor-target gene network

What Caught Our Attention: The researchers were studying how curcumin, a component of the spice turmeric, can inhibit lung cancer metastases. But upon learning that the primary material had been expired at the time of testing (and realizing they were unable to repeat their experiments), the researchers pulled their paper. Expiration dates do have safety factors built in, but attention to such details is imperative in research.  Continue reading Caught Our Notice: What if you find out a paper relied on expired herbal supplement?

Journal bans author for three years after retracting paper with “serious ethical” problems

An anatomy journal has banned a researcher from submitting papers for three years after determining one of his recently published papers suffered from “serious ethical” issues.

According to Jae Seung Kang, associate editor at the journal Anatomy and Cell Biology (ACB), the paper’s sole author—Jae Chul Lee—falsified both his affiliation and approval for conducting animal experiments in the paper, published online in March.

Kang said the journal discovered the issues after Lee submitted other papers to the journal this past August. During the journal’s review process, it discovered “over 70% redundancy”—ie, plagiarism—between the newly submitted papers and two now-retracted papers—the ACB paper as well as a 2015 paper published in the Journal of Pathology and Translational Medicine, on which Jae Chul Lee was corresponding author. The issues prompted the journal to conduct “an in-depth investigation,” Kang said. Continue reading Journal bans author for three years after retracting paper with “serious ethical” problems

Brazil research foundation sues scientist over $103k scholarship

The São Paulo Research Foundation (FAPESP), a state-level agency in Brazil that funds scientific research, is suing Paty Karoll Picardi, a protégé of Brazilian diabetes researcher Mario Saad.

According to a São Paulo Court of Justice website, the reason stated is for “recebimento of bolsa de estudos,“ which translates to “receipt of scholarship.” FAPESP is suing for 334,116 Brazilian Reals ($102,927).

Now, Picardi is counter-suing, according to a case document released Nov. 17 — although we’re not sure for what, and why.  Continue reading Brazil research foundation sues scientist over $103k scholarship

Where’s the data? Authors can’t support figures in 2017 kidney paper

Researchers have retracted a 2017 paper exploring a novel approach to treat kidney injury, because three images were “constructed inappropriately.”

That’s about as much as we know: The retraction notice provides few details about the nature of the issue, only that the authors—most of whom work at Pennsylvania State University College of Medicine in Hershey—could not provide the original data for the recently published figures.

The paper, published in American Journal of Physiology – Renal Physiology, was retracted October 1, just over four months after appearing online in mid-May. Continue reading Where’s the data? Authors can’t support figures in 2017 kidney paper

Caught Our Notice: To know if someone’s been vaccinated, just asking isn’t enough

Via Wikimedia

Title: Hepatitis B Virus Infection in Preconception Period Among Women of Reproductive Age in Rural China – A Nationwide Study

What Caught Our Attention: When researchers set out to study hepatitis B among women in rural China, and they wanted to know if the women had been vaccinated against the virus, they simply asked them. While that can sometimes be useful, apparently it was a mistake in this case, as the reliance on patient memory injected too much doubt into these findings.  Continue reading Caught Our Notice: To know if someone’s been vaccinated, just asking isn’t enough

Caught Our Notice: When authors go MIA, the article may follow

Via Wikimedia

Title: IRF9 inhibits human acute myeloid leukemia through the SIRT1-p53 signaling pathway

What Caught Our Attention: When authors fail to respond to editors’ requests for information, it isn’t hard to imagine that the submitted manuscript will lose its publishing appeal. In this case, the journal and publisher withdrew the article after “repeated attempts” to contact the authors were unsuccessful.

The notice doesn’t say why the journal needed to get in touch with the authors; of course, some authors may cease correspondence for a variety of reasons, but there is usually some backstory. Since the authors disappeared, the withdrawn article has, as well. Continue reading Caught Our Notice: When authors go MIA, the article may follow

Caught Our Notice: Wait…we wrote WHAT paper?

Via Wikimedia

Title: Assessment of coronary heart diseases in diabetics in al-Madinah al-Munawarah

What Caught Our Notice: We’ve seen researchers dinged for adding authors to papers who didn’t participate in the research, but it’s rare to have a notice say co-author signatures were forged. In a recent retraction, the first two authors said the signatures on the the approval document received by the journal do not belong to them. The notice does not indicate which of the remaining two co-authors might be responsible for the forgery. Continue reading Caught Our Notice: Wait…we wrote WHAT paper?

Lancet retracts and replaces news story about controversial abortion drug

The Lancet has retracted a journalist-written piece about a controversial drug used off-label to induce abortions, and replaced it with a corrected version.

In the retraction notice, the journal said it “removed the information that we believe to be inaccurate.”

The article, first published Oct. 28, 2017, highlights Pfizer’s decision to withdraw the drug, misoprostol, from the French market in 2018, and explores the ongoing debate surrounding its uses and safety. Approved to treat ulcers, misoprostol is more often used off-label to induce labor or medical abortions, despite reports of serious side effects, including hemorrhaging and birth defects “sometimes associated with fetal death.” Continue reading Lancet retracts and replaces news story about controversial abortion drug